Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derivative developed at Washington State University. Research indicates it is approximately 10 million times more potent than BDNF at enhancing hepatocyte growth factor (HGF) signaling. It is studied for cognitive enhancement, synaptogenesis, and potential applications in neurodegenerative disease research.
Aliases: N-hexanoic-Tyr-Ile-(6
- Research score
- 5/10
- Reality tier
- experimental
Mechanism
Dihexa binds HGF and prevents its degradation by hepatocyte growth factor activator inhibitor (HAI-1), resulting in amplified HGF/c-Met signaling. This drives synaptogenesis and dendritic spine formation in the hippocampus.
Evidence note
Limited studies from single research group (WSU). Extraordinarily potent in animal models. Zero human clinical data.
Studies
Angiotensin IV analog as procognitive agent
Demonstrated oral bioavailability and blood-brain barrier penetration with profound nootropic effects.
Open source · PMID 22178568Dihexa and cognitive enhancement
Restored cognitive function in animal models of dementia through HGF/c-Met pathway activation.
Open source · PMID 23811393
FAQ
How potent is Dihexa?
Research from Washington State University indicates Dihexa is approximately 10 million times more potent than BDNF at promoting HGF signaling and synaptogenesis.
Is Dihexa orally bioavailable?
Published research indicates oral bioavailability, which is unusual for peptide compounds.
For research and educational use only. This content is not medical advice.